What is Castle Biosciences's market cap?

Castle Biosciences (CSTL) has a market capitalization of $724.6M and trades on NASDAQ.

What is Castle Biosciences's revenue and profitability?

Castle Biosciences generated $339.9M in trailing twelve-month revenue with a net loss of $12.8M, representing a net margin of -3.8%. Gross margin stands at 77.9%, with free cash flow of $4.5M. These figures are based on the Q1 2026 filing.

Who are Castle Biosciences's competitors?

Castle Biosciences's key competitors include Lucid Diagnostics, LabCorp, Veracyte, and others. These companies compete in similar markets and product categories.

Who does Castle Biosciences partner with?

Castle Biosciences's notable partners include SciBase Holding AB, The Washington University, ThermoFisher Scientific, Inc., and others.

What subsidiaries does Castle Biosciences have?

Castle Biosciences's subsidiaries include Previse, AltheaDx, Inc., Cernostics, Inc..

Where is Castle Biosciences headquartered?

Castle Biosciences is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 2019.

Castle Biosciences

CSTL

Castle Biosciences is a molecular diagnostics company that develops and commercializes innovative testing solutions for dermatologic cancers, gastroenterology, and ophthalmology.

Market cap

$724.58M+56.1%

Revenue$339.9M-2.1%

Net income-$12.8M-153%

Free cash flow$4.5M-89.2%

EPS (diluted)-$0.43-126%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$84.2MBeat by $5.0M EPS-$0.49In line

Read the full report

Next report

Jul 30, 2026 (Today)

Revenue estimate$86.2M

EPS estimate-$0.44

Financials

Q1 2026

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation & ratios

Valuation

See full

Market cap$724.58M+56.1%

Enterprise value$697.54M+64.6%

P/S2.1×+0.8×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Segments

By product

See full

Non-Dermatologic$42.6M+70.1%

Dermatologic$41.1M-34.7%

By segment

See full

Reportable Segment$83.7M-4.9%

Competitors

By market cap

Labcorp Holdings$25.8B+18.8%

Veracyte$4.4B+132%

Personalis, Inc.$1.3B+157%

Castle Biosciences$724.6M+54.6%

Myriad Genetics$502.5M+33.0%

Lucid Diagnostics$174.4M+49.3%

Cardio Diagnostics Holdings Inc.$4.6M-31.4%

ONC

Onconetix, Inc.$3.1M+62.2%

By revenue growth

Lucid Diagnostics+23.0%

Veracyte+16.9%

Labcorp Holdings+6.4%

Myriad Genetics-0.3%

Castle Biosciences-2.1%

Personalis, Inc.-24.7%

By net margin

Veracyte16.25%+9.1pp

Labcorp Holdings6.99%+1.3pp

Castle Biosciences-3.78%-2.3pp

Myriad Genetics-48.24%-36.0pp

Personalis, Inc.-148.11%-50.0pp

Lucid Diagnostics-876.72%+605pp

Profile

Castle Biosciences is a molecular diagnostics company that develops and commercializes innovative testing solutions for dermatologic cancers, gastroenterology, and ophthalmology. The company leverages multi-analyte assays with algorithmic analysis and machine learning to provide personalized genomic information that aids clinicians in diagnosis, risk stratification, and treatment selection.

Competitive position

A leading provider of proprietary gene expression profile tests for skin cancer with a significant established market presence in uveal melanoma and expanding footprint in gastroenterology.

GeographiesUnited States

Customer segmentsSpecialist Physicians, Medical Laboratories, Health Insurance Payors

Business modelDiagnostic Testing Services, Direct Sales, Intellectual Property Licensing

SuppliersSole-source reagent suppliers, Laboratory equipment manufacturers, Academic research institutions for IP licensing

CustomersMedicare and government payors, Commercial health insurance companies, Specialty physician clinics, Hospitals

CountryUnited States of America

Listed2019

Employees638.0

CEODerek J. Maetzold

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitecastlebiosciences.com

FilingsSEC EDGAR

Ask your AI about Castle Biosciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's market cap?: Castle Biosciences (CSTL) has a market capitalization of $724.6M and trades on NASDAQ.
What is Castle Biosciences's revenue and profitability?: Castle Biosciences generated $339.9M in trailing twelve-month revenue with a net loss of $12.8M, representing a net margin of -3.8%. Gross margin stands at 77.9%, with free cash flow of $4.5M. These figures are based on the Q1 2026 filing.
Who are Castle Biosciences's competitors?: Castle Biosciences's key competitors include Lucid Diagnostics, LabCorp, Veracyte, and others. These companies compete in similar markets and product categories.
Who does Castle Biosciences partner with?: Castle Biosciences's notable partners include SciBase Holding AB, The Washington University, ThermoFisher Scientific, Inc., and others.
What subsidiaries does Castle Biosciences have?: Castle Biosciences's subsidiaries include Previse, AltheaDx, Inc., Cernostics, Inc..
Where is Castle Biosciences headquartered?: Castle Biosciences is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 2019.